A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 355-365

  Ji, Jianjian ^a   Fan, Hongye ^b   Li, Fanlin ^a   Li, Xiaojing ^a   Dong, Guanjun ^a   Gong, Wei ^a   Song, Yuxian ^a   Liu, Fei ^a   Hua, Chunyan ^a   Tan, Renxiang ^a   Dou, Huan ^a   Hou, Yayi ^a  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

FC 99; Interferon ; Plasmacytoid dendritic cells; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; N 1[(4 METHOXY) METHYL]4 METHYL 1,2 BENZENEDIAMINE; PHENYLENEDIAMINE DERIVATIVE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; ALKANESULFONIC ACID; AUTACOID; CYTOKINE; FLUORAD FC99; FLUOROCARBON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE EXPRESSION; IN VITRO STUDY; KIDNEY; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SPLEEN; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DENDRITIC CELL; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNDROME;

ALKANESULFONATES; ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; FLUOROCARBONS; GENE EXPRESSION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION MEDIATORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; SYNDROME;

EID: 84949556923     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.10.017     Document Type: Article

References (48)

1. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., Murphy E.D., Roths J.B., Dixon F.J. Spontaneous murine lupus-like syndromes. Clinical and immunopathologicalmanifestations in several strains. J. Exp. Med. 1978, 148:1198-1215.
2. Baccala R., Hoebe K., Kono D.H., Beutler B., Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 2007, 13:543-551.
3. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. 2003, 100:2610-2615.
4. Baechler E.C., Gregersen P.K., Behrens T.W. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 2004, 16:801-807.
5. Bagavant H., Deshmukh U.S., Wang H., Ly T., Fu S.M. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J. Immunol. 2006, 177:8258-8265.
6. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
7. Chen M., Wang Y.H., Wang Y., Huang L., Sandoval H., Liu Y.J., Wang J. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006, 311:1160-1164.
8. Colonna L., Dinnall J.A., Shivers D.K., Frisoni L., Caricchio R., Gallucci S. Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus. Arthritis Res. Ther. 2006, 8(2):R49.
9. Decker P., Kötter I., Klein R., Berner B., Rammensee H.G. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006, 45:1087-1095.
10. Ding D., Mehta H., McCune W.J., Kaplan M.J. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J. Immunol. 2006, 177:5878-5889.
11. Dong B., Zhou Q., Zhao J., Zhou A., Harty R.N., Bose S., Banerjee A., Slee R., Guenther J., Williams B.R., Wiedmer T., Sims P.J., Silverman R.H. Phospholipid scramblase 1 potentiates the antiviral activity of interferon. J. Virol. 2004, 78:8983-8993.
12. Dou H., Song Y., Liu X., Yang L., Jiang N., Chen D., Li E., Tan R., Hou Y. A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating pro-inflammatory mediators via IRAK4. Am. J. Respir. Cell Mol. Biol. 2014, 51(2):191-200.
13. Dubois B., Vanbervliet B., Fayette J., Massacrier C., Kooten C., Brière F., Banchereau J., Caux C. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J. Exp. Med. 1997, 185:941-951.
14. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
15. Gong W., Hu E., Dou H., Song Y., Yang L., Ji J., Li E., Tan R., Hou Y. A novel 1,2-benzenediamine derivate FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse septic model. Br. J. Pharmacol. 2014, [Epub ahead of print]. 10.1111/bph.12797.
16. Honda K., Takaoka A., Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
17. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell diferentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
18. Kariuki S.N., Franek B.S., Kumar A.A., Arrington J., Mikolaitis R.A., Utset T.O., Jolly M., Crow M.K., Skol A.D., Niewold T.B. Trait-stratiied genome-wide association study identii es novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12(4):R151.
19. Kaveri S.V., Mouthon L., Bayry J. Basophils and nephritis in lupus. N. Engl. J. Med. 2010, 363(11):1080-1082.
20. Kim T.W., Staschke K., Bulek K., Yao J., Peters K., Oh K.H., Vandenburg Y., Xiao H., Qian W., Hamilton T., Min B., Sen G., Gilmour R., Li X. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J. Exp. Med. 2007, 204(5):1025-1036.
21. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus. Arthritis Rheum. 2005, 52(5):1491-1503.
22. Le Bon A., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., Tough D.F. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 2006, 176:2074-2078.
23. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 2002, 3:822-829.
24. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
25. Lyn-Cook B., Xie C., Oates J., Treadwell E., Word B., Hammons G., Wiley K. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol. Immunol. 2014, 61:38-43.
26. Marshak-Rothstein A., Rifkin I.R. Immunologically active autoantigens: the role of Toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 2007, 25:419-441.
27. Merrill J.T., Wallace D.J., Petri M., Kirou K.A., Yao Y., W White, Robbie I., Levin G., Berney R., Chindalore S.M., Olsen V., Richman N., Le L., Jallal C., White B. Lupus Interferon Skin Activity (LISA) Study Investigators: safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 2011, 70:1905-1913.
28. Monrad S., Kaplan M.J. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol. Res. 2007, 37:135-145.
29. Muñoz L.E., Janko C., Schulze C., Schorn C., Sarter K., Schett G., Herrmann M. Autoimmunity and chronic inflammation-two clearance-related steps in the etiopathogenesis of SLE. Autoimmun. Rev. 2010, 10(1):38-42.
30. Nikpour M., Dempsey A.A., Urowitz M.B., Gladman D.D., Barnes D.A. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann. Rheum. Dis. 2008, 67:1069-1075.
31. Obermoser G., Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010, 19:1012-1019.
32. Oh K., Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 432595.
33. Mina-Osorio P., LaStant J., Keirstead N., Whittard T., Ayala J., Stefanova S., Garrido R., Dimaano N., Hilton H., Giron M., Lau K.Y., Hang J., Postelnek J., Kim Y., Min S., Patel A., Woods J., Ramanujam M., DeMartino J., Narula S., Xu D. Suppression of Glomerulonephritis in pus-Prone NZB NZW Mice by RN486, lective Inhibitor of Bruton's Tyrosine Kinase. Arthritis Rheum. 2013, 9:2380-2391.
34. Patole P.S., Pawar R.D., Lichtnekert J., Lech M., Kulkarni O.P., Ramanjaneyulu A., Segerer S., Anders H.J. Coactivation of toll-like receptor-3 and -7 in immune complex glomerulonephritis. J. Autoimmun. 2007, 29:52-59.
35. Petri M., Singh S., Tesfasyone H., Dedrick R., Fry K., Lal P., Williams G., Bauer J., Gregersen P., Behrens T., Baechler E. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009, 18(11):980-989.
36. Perrin L.H., Lambert P.H., Miescher P.A. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J. Clin. Invest. 1975, 56(1):165-176.
37. Sharma M., Bayry J. Autoimmunity: basophils in autoimmune and inflammatory diseases. Nat. Rev. Rheumatol. 2015, 11(3):129-131.
38. Sinicato N.A., Postal M., Peres F.A., Peliçari Kde O., Marini R., Santos Ade O., Ramos C.D., Appenzeller S. Obesity and cytokines in childhood-onset systemic lupus erythematosus. J. Immunol. Res. 2014, 162047.
39. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
40. Steinmetz O.M., Turner J.E., Paust H.J., Lindner M., Peters A., Heiss K., Velden J., Hopfer H., Fehr S., Krieger T., Meyer-Schwesinger C., Meyer T.N., Helmchen U., Mittrücker H.W., Stahl R.A., Panzer U. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J. Immunol. 2009, 183(7):4693-4704.
41. Stranges P.B., Watson J., Cooper C.J., Choisy-Rossi C.M., Stonebraker A.C., Beighton R.A., Hartig H., Sundberg J.P., Servick S., Kaufmann G., Fink P.J., Chervonsky A.V. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 2007, 26(5):629-641.
42. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
43. Theofilopoulos A.N., Dixon F.J. Etiopathogenesis of murine SLE. Immunol. Rev. 1981, 55:179-216.
44. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 1985, 37:269-390.
45. Wan S., Xia C., Morel L. IL-6 produced by dendritic cells fromlupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 2007, 178(1):271-279.
46. Yamauchi M., Hashimoto M., Ichiyama K., Yoshida R., Hanada T., Muta T., Komune S., Kobayashi T., Yoshimura A. Ifi202: an IFN-inducible candidate gene for lupus susceptibility in NZB/W F1 mice, is a positive regulator for NF-B activation in dendritic cells. Int. Immunol. 2007, 19:935-942.
47. Yokogawa M., Takaishi M., Nakajima K., Kamijima R., Fujimoto C., Kataoka S., Terada Y., Sano S. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol. 2014, 66(3):694-706.
48. Zhuang H., Narain S., Sobel E., Lee P.Y., Nacionales D.C., Kelly K.M., Richards H.B., Segal M., Stewart C., Satoh M., Reeves W.H. Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol. 2005, 117:238-250.